Patient characteristics of 106 FL specimens acquired at diagnosis
| Clinical characteristics . | N = 106 (%) . | Log-rank P value for survival . | Log-rank P value for transformation . |
|---|---|---|---|
| Median age, y | 53 | ||
| Male sex | 59 (56) | .4 | .7 |
| Age > 60 y | 33 (31) | .2 | .5 |
| PS > 1 | 13 (13) | .003 | .3 |
| LDH > normal | 24 (25) | .008 | .1 |
| Extranodal sites > 1 | 13 (12) | .4 | .6 |
| Stage III/IV | 74 (70) | .01 | .1 |
| IPI score | .003 | .02 | |
| 0-1 | 66 (62) | ||
| 2-3 | 34 (32) | ||
| 4-5 | 6 (6) | ||
| Diagnostic pathology | |||
| FOLL1 | 63 (60) | ||
| FOLL2 | 33 (31) | ||
| FOLL3A | 9 (9) | ||
| Primary therapy | |||
| Observation | 26 (24) | ||
| Rad alone | 15 (14) | ||
| Single agent chemo | 12 (11) | ||
| Multi-agent chemo +/− rad | 41 (39) | ||
| Multi-agent chemo + rituximab | 12 (11) | .7 | .7 |
| Outcome | |||
| Transformation | 53 (50) | .02 | |
| Biopsy proven | 34 (64) | .6 | |
| Clinical | 19 (36) | ||
| Death | 45 (42) | ||
| Unrelated | 3 (7) | ||
| From transformation | 29 (64) | ||
| From progressive indolent FL | 13 (29) | ||
| Median follow-up alive = 7.33 y | |||
| Median overall survival = 10.83 y | |||
| Median time to transformation = 6.61 y |
| Clinical characteristics . | N = 106 (%) . | Log-rank P value for survival . | Log-rank P value for transformation . |
|---|---|---|---|
| Median age, y | 53 | ||
| Male sex | 59 (56) | .4 | .7 |
| Age > 60 y | 33 (31) | .2 | .5 |
| PS > 1 | 13 (13) | .003 | .3 |
| LDH > normal | 24 (25) | .008 | .1 |
| Extranodal sites > 1 | 13 (12) | .4 | .6 |
| Stage III/IV | 74 (70) | .01 | .1 |
| IPI score | .003 | .02 | |
| 0-1 | 66 (62) | ||
| 2-3 | 34 (32) | ||
| 4-5 | 6 (6) | ||
| Diagnostic pathology | |||
| FOLL1 | 63 (60) | ||
| FOLL2 | 33 (31) | ||
| FOLL3A | 9 (9) | ||
| Primary therapy | |||
| Observation | 26 (24) | ||
| Rad alone | 15 (14) | ||
| Single agent chemo | 12 (11) | ||
| Multi-agent chemo +/− rad | 41 (39) | ||
| Multi-agent chemo + rituximab | 12 (11) | .7 | .7 |
| Outcome | |||
| Transformation | 53 (50) | .02 | |
| Biopsy proven | 34 (64) | .6 | |
| Clinical | 19 (36) | ||
| Death | 45 (42) | ||
| Unrelated | 3 (7) | ||
| From transformation | 29 (64) | ||
| From progressive indolent FL | 13 (29) | ||
| Median follow-up alive = 7.33 y | |||
| Median overall survival = 10.83 y | |||
| Median time to transformation = 6.61 y |
PS indicates ECOG performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; FOLL1, follicular lymphoma grade 1; FOLL2, grade 2; FOLL3A, grade 3A; rad, radiation; chemo, chemotherapy; and FL, follicular lymphoma.